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Aims: To determine the association of daily and day-to-day glucose variability with oxida-
tive stress.
Methods: This was a cross-sectional analysis of 68 patients with type 2 diabetes mellitus
(T2DM) over 72 h of continuous glucose monitoring. Fasting plasma glucose (FPG) and
hemoglobin A1c (HbA1c) were measured before breakfast on day 1. Glucose variability,
mean glucose level (MGL), mean amplitude of glycemic excursions (MAGE), mean of daily
differences (MODD) in glucose levels and area under the postprandial plasma glucose curve
(AUCPP) were measured on days 2 and 3. Plasma oxidant capacity against N,N-diethylpara
phenylenediamine was measured with the diacron-reactive oxygen metabolites (d-ROMs)
test on day 1.
Results: Overall, 66.2% males with the mean age of 63.2 ± 12.6 years, diabetes duration of
12.9 ± 10.4 years, and HbA1c level of 8.1 ± 1.6% (65 ± 17 mmol/mol) were included. MGL
(r = 0.330), HbA1c (r = 0.326), MAGE (r = 0.565), MODD (r = 0.488), and AUCPP (r = 0.254) exhib-
ited significant correlations with d-ROMs and not FPG; these correlations remained signif-
icant after adjustment for clinical factors (sex, age, duration of diabetes, smoking habit,
insulin use, statin use, angiotensin II receptor blocker use, BMI, LDL-C, HDL-C, TG, eGFR,
and systolic blood pressure) (R2 = 0.268, R2 = 0.268, R2 = 0.417, R2 = 0.314, and R2 = 0.347,
respectively). MAGE was significantly correlated with MODD (r = 0.708) and MAGE and
MODD were independently correlated with d-ROMs by multivariate analysis.
Conclusions: Therefore, oxidative stress is associated with daily and day-to-day glucose
variability in patients with T2DM.
 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 2 2 ( 2 0 1 6 ) 6 2 –7 0 63hydroperoxide; despite its moderate oxidative power, serum
1. Introduction
The United Kingdom Prospective Diabetes Study (UKPDS)
demonstrated that chronic hyperglycemia, as measured by
glycated hemoglobin (HbA1c), is the main risk factor for
diabetes-related complications [1]. However, HbA1c does not
inform us about short-term glycemic variability, which refers
to swings in blood glucose levels throughout the day, includ-
ing the possibilities of hypoglycemic and hyperglycemic peri-
ods within and between days. Recently, continuous glucose
monitoring (CGM) has become increasingly relevant when
evaluating such variability and can detect glucose variability
in greater detail than conventional self-monitoring methods.
Various studies have been conducted on the relationship
between glucose variability and diabetic complications. Post-
prandial plasma glucose (PPG) is more closely related to car-
diovascular disease than fasting plasma glucose (FPG) [2],
with glucose variability considered important in patients with
type 2 diabetes mellitus (T2DM) [3]. In addition, FPG variability
is reportedly associated with the 10-year survival of this
patient group [4], with both intra-day glucose variability and
HbA1c variability being independent risk factors for microan-
giopathy [5,6]. Therefore, glucose variability may be an addi-
tional risk factor for diabetic complications, independent of
hyperglycemia [7]. On the other hand, HbA1c and mean blood
glucose are related to cardiovascular disease in addition to
PPG and glucose variability [8]. Furthermore, a decrease in
glucose variability dose does not reduce the risk of cardiovas-
cular disease in patients with T2DM after acute myocardial
infarction [9]. Furthermore, HbA1c variability is not associ-
ated with microvascular complications in type 1 diabetes
[10]. Based on the abovementioned findings, the relationship
between glucose variability and diabetic complication is
controversial.
Oxidative stress appears important in the development
and progression of diabetic complications [11]. Hyperglycemic
damage results from reactive oxygen species (ROS)-induced
activation of polyol, hexosamine, protein kinase C, and the
advanced glycation end-product pathway [12]. Because
atherosclerosis can result when acute glucose variability
induces endothelial dysfunction through oxidative stress
[13], the activation of oxidative stress could be a risk factor
for diabetic complications. There are various markers of
oxidative stress [14], but 8-hydroxydeoxyguanosine (8-OHdG)
and 8-iso-prostaglandin F2a (8-iso-PGF2a) are particularly use-
ful in diabetes: 8-OHdG has often been used as a biomarker of
oxidative DNA damage [15], whereas 8-iso-PGF2a is a major
product of the peroxidation of unsaturated fatty acids and
can predict oxidative stress [16].
Direct measurement of ROS and free radicals is difficult in
a standard laboratory owing to their biochemical instability,
which requires that the oxidation products of biological com-
ponents be used as markers of oxidative stress. However,
such assays are complex and unsuitable when analyzing a
large number of subjects. Recently, a method of measuring
reactive oxygen metabolites (ROMs) in the blood has been
developed that uses diacron (i.e., the d-ROMs test) [17]. This
photometric test measures the total oxidant capacity of
serum or plasma against the chromogenic substrate N,N-diethylparaphenylenediamine. ROMs mainly comprise organic
levels are detectable because of its relative stability compared
with other free radicals. Not only is the d-ROMs test quick and
inexpensive for use in clinical settings, it is also predictive of
morbidity and mortality [18,19]. Moreover, the test correlates
positively with plasma glucose and HbA1c levels [20], and
levels reduce after antioxidant supplementation in patients
with T2DM [21].
Therefore, we aimed to determine whether daily and day-
to-day glucose variability measured by CGM were associated
with plasma oxidative stress measured by d-ROMs in patients
with T2DM.
2. Subjects, materials and methods
2.1. Subjects
We recruited 68 patients (45 inpatients and 23 outpatients)
with T2DM among those treated at Showa University Hospital
(from October 2013 to May 2015) and Nippon Medical School
(from March 2012 to December 2012). The reasons for hospital
admission were to achieve glycemic control because of poor
control or to evaluate for glucose variability. The inclusion cri-
teria were a diagnosis of T2DM and stable oral hypoglycemic
and/or insulin treatment, both for P3 months before the
study. The exclusion criteria were the use of steroids or
anti-inflammatory drugs, any febrile illnesses within
3 months before the study, and an estimated glomerular fil-
tration rate (eGFR) <30 mL/min/1.73 m2 according to the Cock-
croft–Gault formula [22].
2.2. Study design
This was a cross-sectional analysis of patients with T2DM
over a 72-h period of (CGM).
The following clinical and laboratory parameters were
measured before breakfast on day 1: body mass index, low-
density lipoprotein cholesterol (LDLc), high-density lipopro-
tein cholesterol (HDLc), triglycerides, eGFR, blood pressure,
FPG, and HbA1c. Plasma oxidant capacity against N,N-diethyl
paraphenylenediamine was also measured using the d-ROMs
test on day 1. Glucose variability, mean glucose level (MGL),
mean amplitude of glycemic excursions (MAGE), mean of
daily differences (MODD) in glucose levels, and area under
the PPG curve (AUCPP) were measured on days 2 and 3. Clini-
cal data (age, sex, smoking, and duration of diabetes in years)
were retrieved from medical records.
The study protocol was approved by the ethics committee
of the Showa University School of Medicine. Informed con-
sent was obtained from all subjects after receiving a clear
explanation of the study protocol. The study was designed
in compliance with the Declaration of Helsinki.
2.3. Procedures and measurements
The CGM sensor (CGMS System Gold; Medtronic MiniMed,
Northridge, CA, USA or ipro2; Medtronic MiniMed, Northridge,
CA) was inserted subcutaneously on day 1 and removed on
Fig. 2 – Graphical illustration of mean of daily difference of
blood glucose (MODD).
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and 3 to avoid bias. Venous blood sampleswere drawn for lab-
oratory measurements on day 1 before breakfast. All patients
received a weight-maintaining diet (25–30 kcal/kg ideal body
weight). Glucose variabilities were calculated using CGM data;
the AUCPP was calculated using the incremental areas above
preprandial glucose values beyond 4 h after each meal [23].
The MGL was measured from the date recorded on CGM,
adjusted for self-monitored blood glucose. The mean ampli-
tude of glycemic excursions (MAGE) [24] was calculated to
assess glucose variability (Fig. 1). The mean of the daily differ-
ences (MODD) [25] was calculated as the mean of the absolute
difference between corresponding glucose values on days 2
and 3 (Fig. 2).
2.4. Diagnosis of complications
The presence and severity of diabetic retinopathy was
assessed by ophthalmologists. Fundal assessment was per-
formed by indirect mydriatic examination and slit-lamp
biomicroscopy using a precorneal lens and fluorescein
angiography if needed. Diabetic nephropathy was defined as
follows using the urinary albumin:creatinine ratio (UACR)
based on the first urine sample obtained in the morning: nor-
moalbuminuria, 0–29.9 mg/g creatinine; microalbuminuria,
30–299 mg/g creatinine; and nephropathy, P300 mg/g crea-
tinine [26]. Diabetic neuropathy was defined as the presence
of two or more clinical symptoms (bilateral spontaneous pain,
hypoesthesia, or paraesthesia of the legs), decreased or
absent ankle reflexes, and decreased vibration sensation with
respect to a standard 128-Hz tuning fork.
2.5. Laboratory measurements
Oxidative stress was measured using a d-ROMs test and ded-
icated photometer (F.R.E.E. System; imported by LTD Tokyo
from Diacron International s.r.l. Grosseto, Italy), as previously
reported [27]. According to the Wismerll kinetic procedure,
the change of absorbance per minute was expressed as arbi-Fig. 1 – Graphical illustration of mean amplitude of glycemic
excursions (MAGE).trary units after correction (U.CARR, where 1 U.CARR = the
oxidant capacity of a 0.08 mg/dL H2O2 solution, and the nor-
mal range = 250–300 U.CARR). The intra- and inter-assay coef-
ficients of variation were 2.1% and 3.1%, respectively. We also
measured serum total cholesterol, LDLc, HDLc, triglyceride,
and creatinine levels by an automated analyzer (BM6070;
Japan Electron Optics Laboratory, Tokyo, Japan). Plasma glu-
cose was measured by the glucose oxidase method, and
HbA1c was measured by high-performance liquid chromatog-
raphy [28].
2.6. Statistical analysis
Simple linear correlations were calculated by determining
Pearson’s correlation coefficients with Bonferroni correction
to compare glucose variability and markers of diabetic control
between quartiles of d-ROMs. Multiple stepwise regression
analysis, adjusted for subject characteristics, was performed
to explore the effects of different variables between the
d-ROMs test values and glucose variability as well as to inves-
tigate the influence of different variables on d-ROMs test
values. The level of significance was determined as p < 0.05.
Analyses were performed using IBM SPSS, Version 22, for
Windows (IBM Corp., Armonk, NY). Data are expressed as
means ± standard deviations.
3. Results
3.1. Clinical characteristics
Clinical and laboratory characteristics of the 68 participants
are shown in Table 1, and their treatments are summarized
in Table 2. The study group included more men than women,
and men were slightly overweight. Most participants (n = 64)
were treated with oral glucose-lowering agents or insulin.
Table 2 – Diabetes treatments and other treatments.
Diabetes treatment n (%)
Diabetes therapy
Diet alone 4 (5.9)
Metformin 17 (25.0)
Sulfonylurea 22 (32.4)
Glinide 1 (1.5)
a-glucosidase inhibitor 12 (17.6)
Thiazolidine 10 (14.7)
Dipeptidyl peptidase 4 inhibitor 31 (45.6)
Glucose-like peptide 1 receptor agonist 14 (20.6)
Insulin 24 (35.3)
Other treatments
Lipid-lowering drugs (Statin) 35 (51.5)
Antihypertensive drugs
Angiotensin II receptor blocker 35 (51.5)
Calcium channel blocker 22 (32.4)
Diuretic 6 (8.8)
b blocker 3 (4.4)
a blocker 10 (14.7)
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variables and non-glycemic clinical and laboratory variables
Table 3 shows the correlations between glucose metabolic
variables and d-ROMs. Significant correlations were observed
between d-ROMs and MGL (r = 0.330; p = 0.006), HbA1c
(r = 0.326; p = 0.007), MAGE (r = 0.565; p < 0.001), MODD
(r = 0.488; p < 0.001), and AUCPP (r = 0.254; p = 0.037). However,
d-ROMs did not correlate with FPG. Among the non-glycemic
variables, there was a significant correlation between d-ROMs
and LDLc (r = 0.282; p = 0.020).
Table 4 shows that MGL, HbA1c, and MAGE levels were sig-
nificantly higher in the second to fourth quartiles than those
in the first quartile of d-ROM values. MAGE levels increased
with increasing quartile to a maximum of 130.0 ± 30.5 mg/dL,
whereas MGL and HbA1c levels peaked in the third quartile
(175.4 ± 35.4 mg/dL and 8.6% ± 1.0%, respectively). MODD
levels were also significantly higher in the fourth quartile than
those in the first quartile of the d-ROM results (MODD; fourth
quartile: p = 0.002).
3.3. Linear regression analysis of the associations between
the d-ROMs test results and glucose variability
Multivariate analyses were used to assess the effects of differ-
ent clinical variables and glucose variability parameters onTable 1 – Baseline clinical characteristics of subjects.
Clinical characteristics
Age (years)
Sex (male)
Body mass index (kg/m2)
Smoking (%)
Duration of diabetes (years)
Hypertension
Dyslipidemia
Blood pressure (mm Hg)
Systolic
Diastolic
Low-density lipoprotein cholesterol (mg/dL)
High-density lipoprotein cholesterol (mg/dL)
Triglycerides (mg/dL)
Estimated glomerular filtration rate (ml/min/1.73 m2)
HbA1c (%; mmol/mol)
Mean glucose level (mg/dL)
Markers of glucose variability
MAGE (mg/dL)
MODD (mg/dL)
Fasting plasma glucose state (mg/dL)
AUCPP (mg/dL/h)
d-ROMs (U.CARR)
Macroangiopathy
Nephropathy
Neuropathy
Retinopathy
AUCPP: the total area under the curve of the postprandial plasma glucose
glucose, HbA1c: hemoglobin A1c, MAGE: mean amplitude of glycemic ex
difference of blood glucose.
1 U.CARR (arbitrary unit) = the oxidant capacity of a 0.08 mg/dL H2O2 solutthe activation of oxidative stress. As shown in Table 5, signif-
icant associations existed between d-ROMs and MGL, HbA1c,
MAGE, MODD, and AUCPP but not FPG.Means ± SD, n (%)
63.2 ± 12.6
45 (66.2)
25.2 ± 5.7
13 (19.1)
12.9 ± 10.4
48 (70.6)
49 (72.1)
122.6 ± 17.2
72.3 ± 9.3
99.5 ± 29.2
51.4 ± 19.0
130.7 ± 82.3
79.3 ± 25.8
8.1 ± 1.6 (65 ± 17)
162.2 ± 40.7
105.4 ± 34.9
26.6 ± 9.9
141.6 ± 39.9
320.3 ± 246.0
336.0 ± 49.9
16 (23.5)
31 (45.6)
43 (63.2)
27 (39.7)
, d-ROMs: diacron-reactive oxygen metabolites, FPG: fasting plasma
cursions, MGL: mean glucose level over 24 h, MODD: mean of daily
ion.
Table 3 – Correlations between d-ROMs and markers of diabetic control and non-glycemic metabolic variables.
FPG MGL HbA1c MAGE MODD AUCPP HDL-C LDL-C TG
MGL 0.764**
HbA1c 0.636** 0.693**
MAGE 0.243* 0.482** 0.443**
MODD 0.370** 0.470** 0.319** 0.708**
AUCPP 0.017 0.264* 0.292* 0.606** 0.218
HDL-C 0.064 0.163 0.215 0.182 0.090 0.287*
LDL-C 0.253* 0.342** 0.479** 0.323** 0.226 0.358** 0.209
TG 0.282* 0.243* 0.199 0.185 0.272* 0.039 0.440** 0.178
d-ROMs 0.213 0.330** 0.326** 0.565** 0.488** 0.254* 0.129 0.282* 0.096
FPG: fasting plasma glucose, MGL: mean glucose level over 24 h, HbA1c: hemoglobin A1c, MAGE: mean amplitude of glycemic excursions,
MODD: mean of daily difference of blood glucose, AUCPP: the AUC of the postprandial glucose, HDL-C: high-density lipoprotein cholesterol,
LDL-C: low-density lipoprotein cholesterol, TG: triglyceride, d-ROMs: diacron-reactive oxygen metabolites.
* p < 0.05.
** p < 0.01.
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ROMs test results
Finally, we performed multiple linear regression analyses
with MGL, HbA1c, AUCPP, MAGE, and MODD. In the univariate
analysis, a strong correlation was observed between MAGE
and MODD (r = 0.708, p < 0.001, Fig. 3); therefore, we designed
two independent models: model 1 included MAGE and model
2 included MODD. As shown in Table 6, the substitution of
MODD by MAGE resulted in a significant increase in the coef-
ficient of determination (multiple R2) from 0.226 to 0.309 (i.e.,
an increase of 26.9%).
4. Discussion
To the best of our knowledge, there have been no investiga-
tions on the relationship between oxidative stress and day-
to-day glucose variability in patients with T2DM. This study
is, therefore, the first to demonstrate that oxidative stress is
associated with not only daily but also day-to-day glucose
variability in patients with T2DM; both variabilities correlatedTable 4 – Glucose variability and markers of diabetic control acc
First quartile Second quartil
d-ROMs (U.CARR) 279.9 (245–300) 315.8 (301–329)
N 17 17
FPG (mg/dL) 125.8 ± 34.6 148.7 ± 36.2
MGL (mg/dL) 133.7 ± 26.9 173.5 ± 46.7*
HbA1c (%; mmol/mol) 6.9 ± 1.5; (52 ± 17) 8.5 ± 1.9; (69 ± 2
MAGE (mg/dL) 73.7 ± 16.5 106.1 ± 30.9*
MODD (mg/dL) 21.7 ± 6.4 24.9 ± 9.1
AUCpp (mg/dL/h) 187.7 ± 188.6 348.9 ± 286.0
Specific values when comparing with the first quartile are as follows: MG
quartile: p = 0.020, third quartile: p = 0.007, fourth quartile: p = 0.011; an
quartile: p < 0.001.
AUCPP: the total area under the curve of the postprandial plasma gluco
glucose, HbA1c: hemoglobin A1c, MAGE: mean amplitude of glycemic e
difference of blood glucose.
* p < 0.05; comparison to first quartile.
** p < 0.01; comparison to first quartile.with oxidative stress when compared with sustained hyper-
glycemia. Our findings are clinically relevant and indicate
that therapies should now be evaluated for their potential
to minimize glucose variability and the resulting oxidative
stress.
Previous clinical studies have reported that daily glucose
variability increased oxidative stress in patients with T2DM
[23,29]. In in vitro studies with human endothelial cells, it
has been reported that intermittent high glucose levels stim-
ulated ROS overproduction and increased cellular apoptosis
when compared with a stable high-glucose environment
[30]. Experiments in animals also support the hypothesis that
glucose variability results in endothelial damage [31]. Azuma
et al. showed that repeated glucose variability resulted in sig-
nificant induction of monocyte–endothelial adhesion com-
pared with sustained hyperglycemia [32]. Blood glucose
variability likely accelerated macrophage adhesion to
endothelial cells and promoted the formation of fibrotic arte-
riosclerotic lesions. The same group also showed that reduc-
ing glucose ‘‘swings” was associated with a significant
decrease in monocyte–endothelial adhesion [33,34]. Inording to d-ROMs test results of quartile.
e Third quartile Fourth quartile p
342.3 (330–360) 405.8 (361–459)
17 17
149.7 ± 41.5 142.4 ± 45.3 0.274
175.4 ± 35.4* 166.4 ± 39.7 0.006
1*) 8.6 ± 1.0; (71 ± 11**) 8.6 ± 1.4; (70 ± 15*) 0.003
111.7 ± 34.3** 130.0 ± 30.5** <0.001
26.2 ± 7.2 33.5 ± 12.5** 0.003
354.6 ± 250.8 389.8 ± 246.0 0.073
L: second quartile: p = 0.019, third quartile: p = 0.012; HbA1c: second
d MAGE: second quartile: p = 0.010, third quartile: p = 0.002, fourth
se, d-ROMs: diacron-reactive oxygen metabolites, FPG: fasting plasma
xcursions, MGL: mean glucose level over 24 h, MODD: mean of daily
Table 5 – Linear regression analysis for evaluating associ-
ations between d-ROMs test results and glucose variability.
Dependent variables: d-ROMs (U.CARR)
b coefficient t value p value Full-model R2
(1) FPG
0.767 0.446 0.267
(2) MGL
0.276 2.595 0.012* 0.268
(3) HbA1c
0.253 2.585 0.012* 0.268
(4) MAGE
0.480 4.972 <0.001** 0.417
(5) MODD
0.423 4.087 <0.001** 0.314
(6) AUCpp
0.409 3.896 <0.001** 0.347
AUCPP: the total area under the curve of the postprandial plasma
glucose, d-ROMs: diacron-reactive oxygen metabolites, FPG: fasting
plasma glucose, HbA1c: hemoglobin A1c, MAGE: mean amplitude
of glycemic excursions, MGL: mean glucose level over 24 h, MODD:
mean of daily difference of blood glucose.
Adjusted for sex (female), age, duration of diabetes, smoking habit
(current), insulin use, statin use, angiotensin II receptor blocker use,
body mass index, low-density lipoprotein cholesterol, high-density
lipoprotein cholesterol, triglycerides, estimated glomerular filtration
rate, systolic blood pressure.
* p < 0.05.
** p < 0.01.
Table 6 – Independent effect of markers of diabetic control
on d-ROMs test results.
Dependent variables: d-ROMs (U.CARR.)
b coefficient t value p value Full-model R2
Model 1 <0.001* 0.309
MGL 0.645 0.521
HbA1c 0.829 0.410
AUCPP 1.092 0.279
MAGE 0.565 5.560 <0.001*
Model 2 <0.001* 0.226
MGL 1.062 0.292
HbA1c 1.699 0.094
AUCPP 1.422 0.160
MODD 0.488 4.540 <0.001*
AUCPP: the total area under the curve of the postprandial plasma
glucose, d-ROMs: diacron-reactive oxygenmetabolites, FPG: fasting
plasma glucose, HbA1c: hemoglobin A1c, MAGE: mean amplitude
of glycemic excursions, MGL: mean glucose level over 24 h, MODD:
mean of daily difference of blood glucose.
* p < 0.01.
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the levels of proinflammatory cytokines in normal subjects
and induces endothelial dysfunction in both normal subjects
and patients with T2DM [35].Fig. 3 – Correlation between mean of daily difference of blood g
(MAGE).Although the relationship between oxidative stress and
day-to-day glucose variability in patients with T2DM has
never been reported, Chang et al. demonstrated that variabil-
ity in HbA1c, which reflects longer-term glucose variability, is
associated with oxidative stress in these patients [15]. In addi-
tion, they reported a strong correlation between daily glucose
and HbA1c variability (r = 0.730); this was consistent with our
results that show a strong correlation between daily and day-
to-day glucose variability (r = 0.703). Thus, short- (daily and
day-to-day glucose variability) and long-term glucose variabil-lucose (MODD) and mean amplitude of glycemic excursions
68 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 2 2 ( 2 0 1 6 ) 6 2 –7 0ity (HbA1c and FPG variability) may be associated. Therefore,
acute and chronic variability in blood glucose levels appear to
contribute to increased oxidative stress.
In patients with T2DM, glycemic control has previously
been associated with d-ROMs [20], but no reports have indi-
cated a relation between oxidative stress and glucose variabil-
ity using this test. Although other oxidative stress markers
reflect in vivo metabolites produced by reactive oxygen, the
d-ROMs test reflects the plasma concentration of all free rad-
icals, as validated against the gold standard method of elec-
tron spin resonance spectrometry [36]. We showed that the
d-ROMs test, with other markers of oxidative stress, corre-
lated with glucose variability in patients with T2DM.
Monnier et al. reported that the three main components
that contribute to tissue exposure in hyperglycemia are
HbA1c, FPG, and PPG [37]. Elevated FPG levels have long been
reported to induce oxidative damages, such as lymphocytic
DNA damage, in patients with T2DM [38], but PPG is also
believed to induce oxidative stress and interfere with normal
endothelial function via ROS overproduction [39]. Further-
more, correlations between blood concentrations of HbA1c
and antioxidant values have been reported [40]. However,
we found no association between FPG and d-ROMs, with the
multivariate analysis showing that MAGE and MODD were
most effective in inducing oxidative stress. Although PPG
has been shown to be an independent factor for risk stratifi-
cation for cardiovascular events and total mortality [2,3,41],
our results could explain the differences observed between
the influences of daily glucose variability and PPG. Further-
more, we showed that daily glucose variability was more
effective than PPG in the development of oxidative stress.
Therefore, we suggest that the triggering effect of acute (daily
and day-to-day) glycemic variability on oxidative stress
should be investigated beyond acute post-meal spikes [42,43].
We showed that glucose variability and oxidative stress
increased in tandem, but there was no corresponding
decrease in glycemic control (HbA1c and MGL). Ikebuchi
et al. demonstrated that glycemic control was independently
associated with increasing oxidative stress levels in patients
with T2DM [20], with statistically significant differences
between groups with HbA1c levels of 6.2–6.8% and either
6.9–8.3% or 8.4–10.3%; however, there was no significant dif-
ference between groups with HbA1c levels of 6.9–8.3% and
8.4–10.3%. Thus, there may be a threshold above which oxida-
tive stress occurs during poor glycemic control. Another study
has reported that HbA1c levels of >7% and >6.5% were associ-
ated with increased risks of macrovascular and microvascular
events, respectively [44]. The onset and progression of dia-
betic complications may only occur when the HbA1c exceeds
7%, corresponding with the onset of oxidative stress. Our
analysis of quartiles also showed that the average HbA1c in
the first quartile of d-ROMs value (the first quartile corre-
sponds to normal values of d-ROMs) is 6.9%. This emphasizes
the need to maintain HbA1c levels below 7%, with minimal
glucose variability.
The present study had several limitations. First, we
included inpatients and outpatients, with the possibility that
diets differed between these groups. Second, this study was
cross-sectional, precluding evaluation of any cause–effect
relationship between glucose variability and oxidative stress.Whether intervention aimed at reducing glucose variability
should be administered needs further examination. Third,
the sample size was relatively small; therefore, any subgroup
comparisons may lack statistical power. Fourth, we did not
measure other markers of oxidative stress or antioxidant
potential for comparison. Fifth, we calculated MODD by mea-
suring glucose levels continuously only for 2 days, as reported
by Wentholt et al. [45–47]. In future, MODD should be calcu-
lated based on the absolute difference between the minimum
and maximum daily glycemic variability using CGM for
7 days.
In conclusion, this is the first study to show that oxidative
stress is associated with both daily and day-to-day glucose
variability in patients with T2DM. Further well-designed stud-
ies are necessary to investigate not only the relationship
between glucose variability and oxidative stress in patients
with T2DM but also the relationship and between glucose
variability and endothelial function.
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